BioLineRx (BLRX) Competitors $4.36 -0.11 (-2.46%) Closing price 07/21/2025 04:00 PM EasternExtended Trading$4.34 -0.02 (-0.46%) As of 07/21/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. CNTB, OTLK, VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, and BMEAShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Connect Biopharma (CNTB), Oncobiologics (OTLK), Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Connect Biopharma Oncobiologics Verrica Pharmaceuticals Adaptimmune Therapeutics Milestone Pharmaceuticals Surrozen Pyxis Oncology Alto Neuroscience Maxpro Capital Acquisition Biomea Fusion BioLineRx (NASDAQ:BLRX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Do institutionals & insiders have more ownership in BLRX or CNTB? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to BLRX or CNTB? In the previous week, Connect Biopharma had 6 more articles in the media than BioLineRx. MarketBeat recorded 6 mentions for Connect Biopharma and 0 mentions for BioLineRx. Connect Biopharma's average media sentiment score of 0.08 beat BioLineRx's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Overall Sentiment BioLineRx Neutral Connect Biopharma Neutral Which has higher valuation & earnings, BLRX or CNTB? BioLineRx has higher revenue and earnings than Connect Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.64-$9.22M-$8.80-0.50Connect Biopharma$26.03M4.27-$15.63MN/AN/A Do analysts recommend BLRX or CNTB? BioLineRx presently has a consensus target price of $26.00, indicating a potential upside of 496.33%. Connect Biopharma has a consensus target price of $7.00, indicating a potential upside of 250.00%. Given BioLineRx's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioLineRx is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BLRX or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to BioLineRx's net margin of -15.21%. Connect Biopharma's return on equity of 0.00% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-15.21% -23.93% -6.80% Connect Biopharma N/A N/A N/A Which has more risk & volatility, BLRX or CNTB? BioLineRx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. SummaryConnect Biopharma beats BioLineRx on 8 of the 14 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.05M$2.44B$5.53B$9.40BDividend YieldN/A1.80%4.00%4.04%P/E Ratio-0.508.2826.9819.12Price / Sales0.64714.72445.0298.80Price / CashN/A22.4924.9928.17Price / Book1.085.008.145.70Net Income-$9.22M$30.99M$3.24B$257.84M7 Day Performance-3.54%3.59%2.58%2.98%1 Month Performance2.83%11.18%8.39%13.28%1 Year Performance-86.58%-1.88%32.70%17.13% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx2.0403 of 5 stars$4.36-2.5%$26.00+496.3%-86.9%$19.05M$28.94M-0.5040Gap DownCNTBConnect Biopharma2.0561 of 5 stars$1.41-7.2%$7.00+396.5%+57.5%$78.34M$26.03M0.00110News CoverageGap UpHigh Trading VolumeOTLKOncobiologics2.064 of 5 stars$2.32+12.1%$9.60+313.8%-74.1%$77.88MN/A-2.5520VRCAVerrica Pharmaceuticals4.1702 of 5 stars$0.82+1.0%$8.00+881.6%-89.1%$75.38M$7.57M-0.6840ADAPAdaptimmune Therapeutics1.9972 of 5 stars$0.28+4.6%$1.35+381.0%-76.4%$74.48M$178.03M-1.04490MISTMilestone Pharmaceuticals2.8249 of 5 stars$1.38-11.5%$7.00+407.2%+0.7%$73.78M$1M-1.7730High Trading VolumeSRZNSurrozen1.8395 of 5 stars$8.61-1.1%$38.50+347.2%-3.3%$73.73M$11.64M-0.3480Positive NewsGap DownPYXSPyxis Oncology1.6833 of 5 stars$1.19+2.6%$9.00+656.3%-67.5%$73.72MN/A-0.7560ANROAlto Neuroscience2.2295 of 5 stars$2.71+4.0%$8.50+214.2%-81.7%$73.22MN/A-1.16N/AJMACMaxpro Capital AcquisitionN/A$5.45-4.4%N/A+2,878.4%$73.18MN/A0.002,021Gap DownBMEABiomea Fusion3.2217 of 5 stars$1.94-3.0%$21.40+1,003.1%-63.7%$72.89MN/A-0.5550Analyst ForecastGap Up Related Companies and Tools Related Companies CNTB Competitors OTLK Competitors VRCA Competitors ADAP Competitors MIST Competitors SRZN Competitors PYXS Competitors ANRO Competitors JMAC Competitors BMEA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
